Serum Institute of India

Serum Institute of India is a vaccine manufacturer that develops, produces, and supplies a wide range of immunobiological products, including vaccines for polio, measles, diphtheria, tetanus, hepatitis B, Haemophilus influenzae type b, and the COVID‑19 vaccine Covishield. Its products are used in routine immunisation programmes as well as in outbreak response and pandemic preparedness efforts across the public and private sectors. The institute serves governments, United Nations agencies, non‑governmental organisations, and private healthcare providers in numerous countries worldwide.

The company is recognised as one of the largest vaccine producers globally, measured by the number of doses manufactured and distributed each year. It operates multiple manufacturing facilities located in India, enabling it to achieve high output volumes while maintaining cost‑effectiveness. Its scale allows it to meet substantial demand from international procurement mechanisms such as Gavi, the Vaccine Alliance, and UNICEF.

Serum Institute of India distinguishes itself through a focus on affordable, high‑volume vaccine production and a track record of obtaining World Health Organization prequalification for many of its products. The institute has cultivated expertise in large‑scale fermentation, formulation, and fill‑finish processes, which supports rapid technology transfer and scale‑up during health emergencies. Its longstanding involvement in national immunisation programmes has positioned it as a key partner in global health security.

Structurally, Serum Institute of India is a privately held enterprise owned by the Poonawalla family, with no publicly disclosed parent company or major external shareholders. It remains headquartered in India, as indicated in the organisational context, and operates as an independent entity within the domestic pharmaceutical landscape.